<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03466827</url>
  </required_header>
  <id_info>
    <org_study_id>TET-SEL</org_study_id>
    <nct_id>NCT03466827</nct_id>
  </id_info>
  <brief_title>Selinexor in Patients With Advanced Thymoma and Thymic Carcinoma</brief_title>
  <acronym>TET-SEL</acronym>
  <official_title>A Phase II Study of Selinexor (KPT-330) in Patients With Advanced Thymic Epithelial Tumour (TET) Progressing After Primary Chemotherapy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Morten Mau-Soerensen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut Curie</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gustave Roussy, Cancer Campus, Grand Paris</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>GSO Global Clinical Research BV</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Karyopharm Therapeutics Inc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to determine the efficacy of selinexor in adults with TETs determined&#xD;
      by overall response rate (RECIST 1.1) in two parallel cohorts of patients with advanced&#xD;
      thymomas or thymic carcinomas. The study is an international, multicenter, open label phase&#xD;
      II trial using Simons two stage design. The study population is adults with histologically&#xD;
      confirmed, advanced, inoperable TETs who are progressing after treatment with least one&#xD;
      platinum containing chemotherapy regimen.&#xD;
&#xD;
      This study is comprised of 2 similar phase II tirals, one running in EU (25 patients) and one&#xD;
      running in US (25 patients).&#xD;
&#xD;
      There are two study arms:&#xD;
&#xD;
      Arm A: Thymoma&#xD;
&#xD;
        -  Stage 1: 15 patients&#xD;
&#xD;
        -  Stage 2: 10 patients&#xD;
&#xD;
      Arm B: Thymic carcinoma&#xD;
&#xD;
        -  Stage 1: 15 patients&#xD;
&#xD;
        -  Stage 2: 10 patients&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Not provided&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">October 12, 2017</start_date>
  <completion_date type="Anticipated">July 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Response Rate</measure>
    <time_frame>24 months</time_frame>
    <description>To determine the overall response rate according to RECIST 1.1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>6 months</time_frame>
    <description>To determine six months progression free survival of patients with TET treated with selinexor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>24 months</time_frame>
    <description>The number of adverse events as determined by Common Terminology Criteria for Adverse Events (CTCAEs) version 4.03</description>
  </secondary_outcome>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Thymoma</condition>
  <condition>Advanced Thymic Epithelial Tumour</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Selinexor</intervention_name>
    <description>Selinexor 60 mg oral tablets will be administered twice weekly, either Monday/Wednesday or on Tuesday/Thursday or on Wednesday/Friday in a 3-weeks-on and 1-week-off Schedule.</description>
    <other_name>KPT-330</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed advanced TET (thymoma or thymic carcinoma)&#xD;
&#xD;
          -  Inoperable per local Investigator (Masaoka Stage III or IV)&#xD;
&#xD;
          -  Progression after treatment with least one platinum containing chemotherapyregimen&#xD;
&#xD;
          -  Measurable disease (RECIST 1.1)&#xD;
&#xD;
          -  Age ≥18 years&#xD;
&#xD;
          -  ECOG PS &lt;2&#xD;
&#xD;
          -  Patients must have recovered from the toxic effects of prior therapy at the time of&#xD;
             initiation of the study drug unless toxicity is stable.&#xD;
&#xD;
          -  A 4 weeks interval from any investigational agents or cytotoxic chemotherapy to start&#xD;
             of study is required&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
          -  Adequate bone marrow function and organ function:&#xD;
&#xD;
               -  Hematopoietic function: total white blood cell count (WBC) ≥ 3000/mm³, absolute&#xD;
                  neutrophil count (ANC) ≥ 1500/mm³, platelet count ≥ 100,000/mm²&#xD;
&#xD;
               -  Hepatic function: bilirubin &lt; 1.5 times the upper limit of normal (ULN), ALT &lt;&#xD;
                  2.5 times ULN or ALT &lt; 5.0 times ULN in the presence of liver metastases&#xD;
&#xD;
               -  Creatinine clearance &gt; 30 ml/min according to Cockcroft-Gault&#xD;
&#xD;
          -  Patients of childbearing potential must agree to use adequate birth control during and&#xD;
             for 3 months after participation in this study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  No significant medical illness that in the investigator's opinion cannot be adequately&#xD;
             controlled with appropriate therapy or would compromise the patient's ability to&#xD;
             tolerate this therapy, including&#xD;
&#xD;
               -  Unstable cardiovascular function&#xD;
&#xD;
               -  Known active hepatitis A, B, or C infection; or known to be positive for HCV RNA&#xD;
                  or HBsAg (HBV surface antigen)&#xD;
&#xD;
               -  Markedly decreased visual acuity&#xD;
&#xD;
               -  Active infection requiring intravenous antibiotics&#xD;
&#xD;
          -  Pregnancy or breast-feeding&#xD;
&#xD;
          -  Symptomatic brain metastasis requiring corticosteroids&#xD;
&#xD;
          -  Uncontrolled autoimmune disorders. Patients with autoimmune disorders under control on&#xD;
             medication may be included. Patients with pure red cell aplasia may be included if&#xD;
             haemoglobin levels are relatively stable on transfusions or medication&#xD;
&#xD;
          -  Any other cancer (excluding radically operated localised squamous skin cancer) with&#xD;
             clinical activity within the last 2 years&#xD;
&#xD;
          -  Significantly diseased or obstructed gastrointestinal tract, malabsorption,&#xD;
             uncontrolled vomiting or diarrhea or inability to swallow oral medications&#xD;
&#xD;
          -  No dehydration of NCI-CTCAE grade ≥ 1&#xD;
&#xD;
          -  Serious psychiatric or medical conditions that could interfere with treatment.&#xD;
&#xD;
          -  No history of organ allograft&#xD;
&#xD;
          -  No concurrent therapy with approved or investigational anticancer therapeutics&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Morten Mau-Soerensen, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Rigshospitalet, Denmark</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Morten Mau-Soerensen, MD, PhD</last_name>
    <phone>+45 3545 0879</phone>
    <email>paul.morten.mau-soerensen@regionh.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kristoffer S Rohrberg, MD, PhD</last_name>
    <phone>+45 3545 6353</phone>
    <email>kristoffer.staal.rohrberg@regionh.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Morten Mau-Soerensen, MD, PhD</last_name>
      <phone>+ 45 3545 0879</phone>
      <email>morten.mau-soerensen@regionh.dk</email>
    </contact>
    <contact_backup>
      <last_name>Kristoffer S Rohrberg, MD, PhD</last_name>
      <phone>+45 3545 6353</phone>
      <email>kristoffer.staal.rohrberg@regionh.dk</email>
    </contact_backup>
    <investigator>
      <last_name>Gedske Daugaard, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospices Civils de Lyon</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marylise Ginoux, Professor</last_name>
      <email>marylise.ginoux@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>Marylise Ginoux, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Intitut Curie</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nicolas Girard, Professor</last_name>
      <email>nicolas.girard2@curie.fr</email>
    </contact>
    <investigator>
      <last_name>Nicolas Girard, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Intitut Gustave Roussy</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Benjamin Besse, Professor</last_name>
      <email>benjamin.besse@gustaveroussy.fr</email>
    </contact>
    <investigator>
      <last_name>Benjamin Besse, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>France</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <study_first_submitted>March 9, 2018</study_first_submitted>
  <study_first_submitted_qc>March 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 15, 2018</study_first_posted>
  <last_update_submitted>March 9, 2018</last_update_submitted>
  <last_update_submitted_qc>March 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Rigshospitalet, Denmark</investigator_affiliation>
    <investigator_full_name>Morten Mau-Soerensen</investigator_full_name>
    <investigator_title>Chief Physician, MD, PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thymoma</mesh_term>
    <mesh_term>Thymus Neoplasms</mesh_term>
    <mesh_term>Neoplasms, Glandular and Epithelial</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

